The Claim
In overweight or obese adults with type 2 diabetes, 14 weeks of liraglutide treatment is associated with increased circulating levels of visfatin and resistin.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In overweight or obese adults with type 2 diabetes, taking liraglutide for 14 weeks results in higher blood levels of visfatin and resistin, two proteins involved in inflammation and insulin signaling.
See the scientific wording
In overweight or obese adults with type 2 diabetes, 14 weeks of liraglutide treatment is associated with increased circulating levels of visfatin and resistin, two adipokines involved in inflammation and insulin signaling, though the clinical significance of these changes remains unclear.
Liraglutide activates receptors on fat cells, causing them to release more visfatin and resistin into the blood.
What the research says
1 studyIn people with type 2 diabetes who are overweight, taking liraglutide for 14 weeks made two fat-related signaling proteins (visfatin and resistin) go up — just like the claim said. We don’t yet know if that’s good or bad, but the study definitely saw the change happen.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.